The temperature-dependent PL analysis in this sample evidences a fast decrease of the luminescence, consistent with the competing non-radiative relaxation processes expected for a large defective SL.
The inset in Figure 1b reports an HR-TEM image of the annealed sample, evidencing a clear crystalline phase for Ge QD with the fringes due to crystalline planes (indicated by red lines and separated by 0.33 nm, as the (111) planes of c-Ge bulk).
We also observed regions with abundant pre-mRNA-seq reads but very low mRNA-seq reads (e.g., Figure 4B, comparing pre-mRNA and mRNA for the hrde-1 mutant sample), evidencing a unique power of pre-mRNA-seq in revealing gene expression activity.
Microstructures as well as magneto-optical observations of plain and thin-wall samples evidenced a reduction of cracks in the thin-wall samples.
The immunohistochemical protocol applied to murine samples evidenced a PrPsc plaque pattern in only the one animal which had a positive result using the Roboscreen® test.
Consequently, the samples evidence a higher resistance to crevice corrosion and a time delay to have the typical bulging corrosion area (the thickening of corrosion products within the overlapped steel/aluminium interface) of single-lap joint is observed.
The surface energy of dental materials was estimated before and after the coating process by contact angle measurements, revealing that the coating produced a considerable change of surface energy in all the tested samples, evidenced by a contact angle reduction from more than 90° to less than 10°.
Of the 93 fully genotyped specimens, six profiles appeared to have a multiple (mostly two) of VNTR sequences in one sample (Table S3), i.e. sequence data suggested the presence of more than one VNTR type at the same locus in these samples (evidenced by a succession of two nucleotides detected at the same point on the sequencing chromatogram).
PCR was successful in both 13-years-old blood samples, evidenced by a 237 bp long MHC class II DRB1 exon2 fragment, amplified by primer pair 2 (DRB1.1 and DRB1.2).
In our sample, we have evidenced a relevant of use of synthetic cannabinoids among both patients (5.8%) and healthy controls (1%).
